10-Q: NeuroPace Q1 2026: Revenue Dip, Gross Margin Boost

NeuroPace reported a slight revenue decrease in Q1 2026 compared to the prior year, primarily due to the termination of a distribution agreement, but saw a significant improvement in gross margin.

Summary

• NeuroPace's revenue for the three months ended March 31, 2026, was $22.1 million, a 2% decrease from $22.5 million in the same period of 2025.
• This revenue decline was mainly attributed to the termination of the DIXI Medical distribution agreement, partially offset by an increase in RNS System unit sales.
• Cost of goods sold decreased by 22% to $4.0 million, leading to a gross profit of $18.0 million.
• Gross margin improved significantly from 77.0% in Q1 2025 to 81.8% in Q1 2026, driven by the exit of the lower-margin DIXI Medical product distribution.
• Operating expenses increased by 5% to $23.6 million, with sales and marketing up 5% and general and administrative expenses up 20%, while research and development expenses decreased by 3%.
• The company reported a net loss of $6.7 million for the quarter, a slight increase from $6.6 million in the prior year.
• As of March 31, 2026, the company had $54.0 million in cash, cash equivalents, and short-term investments, with $59.0 million in outstanding debt.
• Management believes current liquidity is sufficient for at least the next 12 months of operations.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While the improved gross margin is a positive, the slight decrease in revenue and increase in operating expenses, particularly G&A, alongside a continued net loss, present challenges.

Positives

• Gross margin improved to 81.8% from 77.0% due to the cessation of DIXI Medical product sales.
• RNS System unit sales increased, driven by a higher number of initial implants and replacements.
• Research and development expenses decreased by 3% to $7.2 million.
• The company remains compliant with its MidCap Credit Agreement covenants.
• Cash, cash equivalents, and short-term investments totaled $54.0 million as of March 31, 2026.

Negatives

• Revenue decreased by 2% to $22.1 million due to the termination of the DIXI Medical distribution agreement.
• Net loss increased slightly to $6.7 million from $6.6 million.
• General and administrative expenses increased by 20% to $4.8 million.
• Sales and marketing expenses increased by 5% to $11.6 million.
• The company has an accumulated deficit of $559.1 million as of March 31, 2026.

Risks

• Reliance on the RNS System as the primary source of revenue, with potential negative impacts if market acceptance or sales are not maintained or expanded.
• Dependence on a limited number of single-source suppliers for product manufacturing, creating vulnerability to supply shortages and price fluctuations.
• Inability to accurately forecast customer demand, which could lead to excess inventory write-downs or shortages.
• Competition from alternative treatment options for drug-resistant focal epilepsy, including surgical and other neuromodulation devices.
• Potential unavailability or unfavorable changes in reimbursement for RNS System implantation and ongoing patient care.
• Risk of negative patient outcomes due to inadequate training for neurosurgeons and epileptologists using the RNS System.
• Inability to achieve or maintain satisfactory pricing and margins for the RNS System.
• Potential harm to growth prospects if expanded FDA labeling for generalized epilepsy or pediatric patients is not achieved or is delayed.
• Penalties and harm to business if the company fails to comply with U.S. federal and state healthcare laws and regulations.
• Potential delays in FDA reviews due to recent changes in staffing levels, impacting growth potential and financial plans.
• Risks associated with data privacy and security laws, with potential for significant costs, liabilities, and reputational damage.
• Inability to obtain, maintain, protect, enforce, and defend patent or other intellectual property protection.
• Continued history of net losses and expectation of future losses for the foreseeable future.
• Potential default on the MidCap Term Loan if covenants are not met, leading to acceleration of debt repayment.
• Material impact on revenue growth, financial condition, and results of operations from the expiration of the DIXI Medical distribution agreement.
• Potential for actual operating results to differ significantly from any provided guidance.
• Inability to accurately estimate market opportunity and forecasts of market and revenue growth.
• Potential harm to growth prospects if the company's unique data asset and analysis capabilities are not successfully leveraged.
• Difficulties in obtaining regulatory clearance or approval, or in successfully marketing the RNS System internationally.
• Adverse impacts from future legislation, changes in federal regulatory agency leadership, and new administration policies.
• Potential for product liability lawsuits leading to substantial liabilities and limitations on product marketing and sales.
• Failure of third parties to meet their contractual, regulatory, and other obligations could adversely affect the business.
• Disruptions at government agencies like the FDA and SEC due to funding shortages or shutdowns could hinder operations.

Future Outlook

The company expects to continue incurring net losses and negative cash flows in the near term due to ongoing investments in research and development, clinical studies, and commercial activities. Management believes its current cash, cash equivalents, and short-term investments are sufficient to fund operations for at least the next 12 months. The company may seek additional capital through future equity or debt financings.

Management Comments

• Management believes that the therapeutic advantages of our RNS System, combined with the insights obtained from our extensive brain data set, offer a significant leap forward in epilepsy treatment.
• We believe that a pipeline of product enhancements and new products that improve effectiveness, safety and ease of use is important for supporting increased adoption of our RNS System.
• We believe that successfully training, developing and retaining our Therapy Consultants and Field Clinical Engineers will be required to achieve growth.
• Management believes that our existing cash, cash equivalents and short-term investments will allow us to continue our operations for at least the next 12 months.

Industry Context

StockSavvy.ai notes that NeuroPace's Q1 2026 results reflect the ongoing challenges and opportunities within the medical device sector, particularly for companies focused on specialized neurological treatments. The shift in gross margin due to the DIXI Medical agreement termination highlights the impact of strategic partnerships and their eventual conclusion on financial performance. The company's continued investment in R&D and market expansion for its RNS System aligns with industry trends of seeking advanced, personalized treatment solutions.

Legal Proceedings

• The company is not currently a party to any material legal proceedings that, if determined adversely, would individually or taken together have a material adverse effect on its business, financial position, results of operations or cash flows.

Related Party Transactions

• In February 2025, the company used $49.5 million of net proceeds from a follow-on offering to repurchase all shares held by its significant stockholder, KCK Ltd.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Creditors may be impacted by the company's debt obligations and covenants under the MidCap Credit Agreement.
• Employees' job security and compensation may be influenced by the company's financial performance and growth prospects.
• Customers (hospitals and clinicians) rely on the continued availability and efficacy of the RNS System and may be affected by supply chain issues or regulatory changes.
• Suppliers may be impacted by changes in demand for components and materials.

Next Steps

• Continue investing in research and development, clinical studies, and regulatory affairs to support existing and expanded indications for the RNS System.
• Make significant investments in sales and marketing efforts to drive awareness and expand the referral channel.
• Continue to develop AI-enabled software tools leveraging iEEG data.
• Potentially acquire or invest in additional businesses, products, or technologies.
• Complete the return of remaining DIXI inventory by June 30, 2026.
• Anticipate potential NAUTILUS PMA-S approval in mid-2026 for expanded indication in generalized epilepsy.

Key Dates

Recommendation

The company shows progress in improving its core product's gross margin and expanding its market indications, which are positive long-term indicators. However, the continued net loss, increased G&A expenses, and the impact of exiting a distribution agreement temper immediate enthusiasm. The company's liquidity appears adequate for the near term, but future capital needs and the success of its R&D pipeline are key factors. A 'hold' recommendation reflects a balanced view of these positive developments and ongoing financial challenges.

Keywords

NeuroPace, 10-Q, SEC Filing, Epilepsy, RNS System, Neuromodulation, Medical Device, Financial Results, Revenue, Gross Margin, Net Loss, Debt, Liquidity, FDA, Clinical Trials